Sygnature Discovery has acquired Alderley Oncology, a focused in vivo pharmacology service provider which undertakes in vivo services for cancer drug discovery, strengthening its oncology and immuno-oncology capabilities.
The acquisition will add significant in-house expertise at Nottingham-based Sygnature in the design, conduct and interpretation of pivotal oncology in vivo pharmacology experiments that help identify promising pre-clinical candidates.
Alderley Oncology was established by Jane Kendrew in 2017. “We are delighted to be joining Sygnature Discovery,” Kendrew said. “We look forward to working as part of a fully-integrated team serving the oncology and immuno-oncology drug discovery community, with the ultimate aim of helping patients living with cancer.”
Dr Stuart Onions, Director of Research Management at Sygnature, said: “We are pleased to welcome Jane and Alderley Oncology to Sygnature Discovery.
“The team’s expertise in oncology and immuno-oncology in vivo models will significantly enhance our integrated oncology provision, delivering further value to our integrated projects for clients and, importantly, allow us to more efficiently and effectively deliver potential new therapeutics into pre-clinic development.”
Sygnature CEO Dr Simon Hirst added: “The acquisition of Alderley Oncology expands and enhances our drug discovery services portfolio, and further boosts our on-going investments in oncology.
“We have already delivered five oncology pre-clinical candidates for clients. Sygnature has an expanding portfolio of integrated programmes in oncology and immuno-oncology with clients in the USA and Europe. The added expertise gained from Alderley Oncology will greatly assist in advancing these projects into pre-clinical development.”
Dr Kath Mackay, Managing Director of Bruntwood SciTech – Alderley Park, added: “We’re really proud of the amazing work Jane and her team have delivered over the last three years to create Alderley Oncology and grow it into a successful business. Now is the time for it to scale with the support of Sygnature and accelerate its growth, so that it can play an ever more critical role in supporting UK and global oncology development.”